Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Midday movers: Macy’s, Broadcom, Eli Lilly and more

Published 11/12/2023, 13:22
Updated 11/12/2023, 17:20

Investing.com -- Main U.S. indexes were mixed on Monday as investors geared up for the Federal Reserve's upcoming two-day policy meeting later this week.

Here are some of the biggest U.S. stock movers today:

Macy’s (M) shares surged 19% on reports of a $5.8 billion buyout offer from real estate-focused investing business Arkhouse Management and global asset manager Brigade Capital Management.

U.S. health insurer Cigna (NYSE:CI) shares gained 16% after it reportedly ended talks to acquire peer Humana (NYSE:HUM), pulling the plug on a deal that would have created an insurance behemoth worth over $140 billion. Cigna also unveiled an additional $10 billion in share buybacks.

Sea Ltd ADRs (NYSE:SE) dropped 6.2% after ByteDance's TikTok said it will merge its Indonesian e-commerce business with GoTo's Tokopedia. The announcement fueled concerns around increased competition for the tech conglomerate's e-commerce subsidiary in Indonesia.

Nike (NYSE:NKE) shares climbed 2.5% after Citi improved its rating of the athletic apparel business to "buy" from "neutral," citing signs of margin recovery in a "choppy" macroeconomic environment.

Snap (SNAP) shares were higher by 4.6% after Wells Fargo (NYSE:WFC) analysts raised their recommendation of the social media platform to "overweight" from "equal-weight."

Affimed (NASDAQ:AFMD) shares slumped 7%, paring back earlier gains, after the drugmaker said it would discontinue enrollment in two trial cohorts for its AFM24-102 lung cancer treatment.

Broadcom (NASDAQ:AVGO) climbed 7% following a new Buy rating and $1,100 price target from Citi. Analysts said AI tailwinds offset the semiconductor downturn.

Eli Lilly (NYSE:LLY) declined 4% after full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association. People on Zepbound who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Additional reporting by Louis Juricic

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.